Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose intermittent sunitinib vs lomustine in recurrent glioblastoma multiforme
2016-001797-15Phase 2Terminated
- Sponsor
- VU University Medical Center, Department of Medical Oncology
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sunitinib in glioblastoma (GBM) (2 arms), sponsored by VU University Medical Center, Department of Medical Oncology. Primary endpoint: Six-month progression-free survival (PFS6). Started Jul 2016; status: terminated.
02
Drugs
sunitinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2016-001797-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001797-15.